Clinical Trials

375 enrolled

Urinary Bladder Neoplasms

NCT06731907 2026-05-26

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT07221474 2026-05-26

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT07353957 2026-05-26

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

180 enrolled

Lung Neoplasms

NCT01174121 2026-05-22

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04858269 2026-05-22

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06041503 2026-05-22

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

68 enrolled

Adenocarcinoma of the Bladder

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Hodgkin Disease

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02965716 2026-05-20

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

43 enrolled 18 charts

Melanoma

NCT03430700 2026-05-20

PROMPT

20 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast

Breast Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast

Breast Neoplasms

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05761951 2026-05-19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07486817 2026-05-19

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

60 enrolled

Lung Neoplasms

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04032418 2026-05-18

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

9 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

36 enrolled

Melanoma

NCT05355051 2026-05-18

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

24 enrolled

Hodgkin Disease

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

46 enrolled

DermatologicHead & NeckThoracic

Endometrial Neoplasms

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04565496 2026-05-15

PEM-PRO

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05221645 2026-05-15

P+R-ICE

65 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Phase 2 Terminated

16 enrolled 13 charts

Oligoprogressive

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

240 enrolled

Muscle-invasive Bladder Cancer

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

58 enrolled 13 charts

Prostatic Neoplasms

NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Melanoma

NCT07089992 2026-05-14

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

32 enrolled

Sarcoma

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

NCT02841748 2026-05-13

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

100 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03304639 2026-05-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

9 enrolled 11 charts

Carcinoma, Merkel Cell

NCT04164082 2026-05-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

161 enrolled

Urinary Bladder Neoplasms

NCT04165096 2026-05-13

MK-3475-01C

128 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04369937 2026-05-13

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

18 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT04379596 2026-05-13

DG-03

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04548752 2026-05-13

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05172258 2026-05-13

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

52 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05239624 2026-05-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT05775289 2026-05-13

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Other solid neoplasmThoracic

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT07172256 2026-05-13

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05420948 2026-05-12

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

30 enrolled